Adults 50–59 Years Older May Benefit from GSK's RSV Vaccine.

Published Date: 28 Oct 2023

According to GSK, the respiratory syncytial virus vaccine it developed to protect adults between the ages of 50 and 59 from the illness that results in thousands of hospital admissions and deaths every year showed encouraging preliminary results in a late-stage trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot